Clinical & Translational Immunology (Jan 2023)

Antibody glycosylation correlates with disease progression in SIV‐Mycobacterium tuberculosis coinfected cynomolgus macaques

  • Ebene R Haycroft,
  • Timon Damelang,
  • Ester Lopez,
  • Mark A Rodgers,
  • Bruce D Wines,
  • Mark Hogarth,
  • Cassaundra L Ameel,
  • Stephen J Kent,
  • Charles A Scanga,
  • Shelby L O'Connor,
  • Amy W Chung

DOI
https://doi.org/10.1002/cti2.1474
Journal volume & issue
Vol. 12, no. 11
pp. n/a – n/a

Abstract

Read online

Abstract Objectives Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. Methods Here, we used a simian immunodeficiency virus (SIV)/TB‐coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV‐negative (n = 8) and SIV‐positive (n = 7) MCM 8‐week postinfection with Mycobacterium tuberculosis (Mtb). Results Antibody responses to Mtb were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8‐week post‐Mtb infection, including increased agalactosylation (G0) and reduced di‐galactosylation (G2), which correlated with endpoint Mtb bacterial burden and gross pathology scores, as well as the time‐to‐necropsy. Conclusion These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression.

Keywords